Compare · JNJ vs MPLT
JNJ vs MPLT
Side-by-side comparison of Johnson & Johnson (JNJ) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 441.2x MPLT ($1.27B).
- Over the past year, JNJ is up 50.5% and MPLT is up 58.7% - MPLT leads by 8.2 points.
- JNJ has been more active in the news (8 items in the past 4 weeks vs 3 for MPLT).
- JNJ has more recent analyst coverage (25 ratings vs 10 for MPLT).
- Company
- Johnson & Johnson
- MapLight Therapeutics Inc.
- Price
- $233.65+0.40%
- $29.00+3.31%
- Market cap
- $560.33B
- $1.27B
- 1M return
- +5.03%
- -0.60%
- 1Y return
- +50.52%
- +58.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 10
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
Latest MPLT
- UBS initiated coverage on MapLight Therapeutics with a new price target
- Craig Hallum initiated coverage on MapLight Therapeutics with a new price target
- Chief Executive Officer Kroeger Christopher A. sold $3,215,000 worth of Voting Common Stock (118,235 units at $27.19) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 1,394,094 units (SEC Form 4)
- SEC Form 10-Q filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- Chief Medical Officer Foff Erin Pennock sold $126,640 worth of Voting Common Stock (4,438 units at $28.54) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 346,059 units (SEC Form 4)
- General Counsel Hanson Kristopher sold $419,263 worth of Voting Common Stock (13,917 units at $30.13) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 162,331 units (SEC Form 4)
- Chief Executive Officer Kroeger Christopher A. sold $1,949,634 worth of Voting Common Stock (68,491 units at $28.47) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,512,329 units (SEC Form 4)
- Chief Scientific Officer Lillie James Woodruff sold $20,390 worth of Voting Common Stock (721 units at $28.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.30% to 242,729 units (SEC Form 4)